Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
FBRX vs LCTX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
FBRX Captures Overall Composite Edge (52.7 HOLD vs 54.9 HOLD), While LCTX Leads 3–2 on Growth & Valuation Pillars
FBRX Overall Winner
6-Pillar Tally: FBRX 2 – 3 LCTX (1 Tie)
Matrix Metrics: FBRX 5 – 5 LCTX
As of Nov 20, 2026, Forte Biosciences, Inc. (FBRX) captures the overall head-to-head institutional edge over Lineage Cell Therapeutics, Inc. (LCTX) on higher Unified Composite conviction (52.7/100 HOLD vs. 54.9/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while LCTX wins 3–2 across the 6-pillar growth and valuation breakdown. FBRX trades at $76.99 (N/M Forward P/E, 0.0% operating margin) versus LCTX at $0.77 (30.7x Forward P/E, -280.3% operating margin).
- Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. FBRX 52.7/100 HOLD), FBRX captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -280.3% operating margin) and revenue trajectory (+0.0% vs. -61.0% YoY).
- Technical & Structure Timing Caution: FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About FBRX vs LCTX
FBRX
Head-to-Head Winner
Forte Biosciences, Inc. Common Stock
$76.99
+0.03% 1D
Market Cap
$1.6B
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.09β · 3% Vol
Unified Composite Score
52.7
HOLD
Tech 49.0
Fund 51.0
Flow 62.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
LCTX
Lineage Cell Therapeutics, Inc.
$0.77
-5.87% 1D
Market Cap
$207.4M
TTM Revenue
$11M
Forward P/E
30.7x
Beta / 30D Vol
1.39β · 79% Vol
Unified Composite Score
54.9
HOLD
Tech 40.0
Fund 54.0
Flow 72.0
Mom 45.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (FBRX 2 – 3 LCTX)
1. Valuation Multiples
LCTX
Forward P/E
N/M
30.7x
Trailing P/E
N/M
30.7x
PEG Ratio
N/M
10.64x
EV / Revenue
N/M
15.9x
2. Growth & Scale
FBRX
Revenue Growth (YoY)
+0.0%
-61.0%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$11M
Market Cap
$1.6B
$207.4M
3. Profitability & Quality
LCTX
Gross Margin
N/A
-95.0%
Operating Margin
0.0%
-280.3%
Net Profit Margin
0.0%
16.2%
Return on Equity (ROE)
-62.3%
4.3%
4. Balance Sheet & Cash Flow
LCTX
Cash Generation (TTM)
-$72M
-$24M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$7.52 Book/Sh · -62.3% ROE
$35M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
FBRX
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
11.1% (3rd %ile)
0.0% (<1st %ile)
Put/Call OI Skew
0.77x (Call-Skewed)
N/A
OBV Trend / Tech Phase
NEUTRAL · Markup
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: FBRX (5) vs LCTX (5)| Institutional Metric | FBRX | LCTX | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.6B | $207.4M | FBRX | |
| Trailing P/E Ratio | N/M | 30.7x | LCTX | |
| Forward P/E Ratio | N/M | 30.7x | LCTX | |
| Revenue Growth (YoY) | +0.0% | -61.0% | FBRX | |
| Operating Margin (TTM) | 0.0% | -280.3% | FBRX | |
| Net Profit Margin | 0.0% | 16.2% | LCTX | |
| Return on Equity (ROE) | -62.3% | 4.3% | LCTX | |
| 52-Week Range Position | 100% ($10–$77) | 0% ($1–$2) | FBRX | |
| Beta / 30D Volatility | 1.09β · 3% Vol | 1.39β · 79% Vol | FBRX | |
| Unified Institutional Score | 52.7 / 100 (HOLD) | 54.9 / 100 (HOLD) | LCTX | |
| Trailing 12M Revenue (USD) | N/A | $11M | Scale | |
| Gross Profit Margin (TTM) | N/A | -95.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | 10.64x PEG · 15.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$72M ($7.52 Book/Sh · -62.3% ROE) | -$24M ($35M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
LCTX +4.23 pp
3M Horizon
FBRX +272.44 pp
6M Horizon
FBRX +211.76 pp
1Y Horizon
FBRX +345.99 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FBRX Revenue | LCTX Revenue | FBRX Op. Margin | LCTX Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $20M | $0M | -254.2% | -837.9% | FBRX |
| FY2019 | $0M | $0M | -11288.9% | -1106.0% | LCTX |
| FY2020 | N/A | $0M | N/A | -1448.4% | LCTX |
| FY2021 | N/A | $0M | N/A | -1133.6% | LCTX |
| FY2022 | N/A | $10M | N/A | -153.2% | LCTX |
| FY2023 | N/A | $10M | N/A | -276.5% | LCTX |
| FY2024 | N/A | $10M | N/A | -226.1% | LCTX |
| FY2025 | N/A | $10M | N/A | -251.6% | LCTX |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
FBRX
UNCLASSIFIED
Current IV
11.1%
IV Percentile
3rd %ile
Put/Call OI Skew
0.77x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact FBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
LCTX
BREAKDOWN
Current IV
0.0%
IV Percentile
<1st %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
FBRX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
LCTX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ FBRX vs LCTX Key Questions & Quantitative Answers
As of Nov 20, 2026, Forte Biosciences, Inc. (FBRX) captures the overall head-to-head institutional edge over Lineage Cell Therapeutics, Inc. (LCTX) on higher Unified Composite conviction (52.7/100 HOLD vs. 54.9/100 HOLD) after splitting the core matrix 5–5 (led by Growth & Scale, Options & Positioning), while LCTX wins 3–2 across the 6-pillar growth and valuation breakdown. FBRX trades at $76.99 (N/M Forward P/E, 0.0% operating margin) versus LCTX at $0.77 (30.7x Forward P/E, -280.3% operating margin). Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. FBRX 52.7/100 HOLD), FBRX captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -280.3% operating margin) and revenue trajectory (+0.0% vs. -61.0% YoY). Technical & Structure Timing Caution: FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7); meanwhile LCTX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FBRX leads the Growth & Scale pillar: FBRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LCTX at -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FBRX cumulative revenue shifted N/A while LCTX shifted +0.0%. In operating R&D and SG&A reinvestment, FBRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LCTX.
LCTX screens cheaper on headline valuation multiples. FBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 15.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FBRX (-62.3% ROE) versus LCTX (4.3% ROE) capital efficiency.
In options market volatility and institutional positioning, FBRX carries 11.1% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 3% Vol realized risk). By comparison, LCTX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.39β · 79% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
LCTX vs FBRX · Reverse Pair
FBRX vs KRSA
· Sector Peer
FBRX vs DMRA
· Sector Peer
LCTX vs XERS
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking